133 related articles for article (PubMed ID: 9481233)
1. Assessing cost-effectiveness analyses in rheumatoid arthritis and osteoarthritis.
Ruchlin HS; Elkin EB; Paget SA
Arthritis Care Res; 1997 Dec; 10(6):413-21. PubMed ID: 9481233
[TBL] [Abstract][Full Text] [Related]
2. Socioeconomic evaluation of rheumatoid arthritis and osteoarthritis: a literature review.
Rothfuss J; Mau W; Zeidler H; Brenner MH
Semin Arthritis Rheum; 1997 Apr; 26(5):771-9. PubMed ID: 9144852
[TBL] [Abstract][Full Text] [Related]
3. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK.
Moore A; Phillips C; Hunsche E; Pellissier J; Crespi S
Pharmacoeconomics; 2004; 22(10):643-60. PubMed ID: 15244490
[TBL] [Abstract][Full Text] [Related]
4. Evidence-based medicine is affordable: the cost-effectiveness of current compared with optimal treatment in rheumatoid and osteoarthritis.
Andrews G; Simonella L; Lapsley H; Sanderson K; March L
J Rheumatol; 2006 Apr; 33(4):671-80. PubMed ID: 16541479
[TBL] [Abstract][Full Text] [Related]
5. Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective.
Bessette L; Risebrough N; Mittmann N; Roussy JP; Ho J; Zlateva G
J Med Econ; 2009 Sep; 12(3):246-58. PubMed ID: 19743942
[TBL] [Abstract][Full Text] [Related]
6. Health services research in rheumatology: a great deal accomplished, a great deal left to do.
Usman Iqbal S; Prashker M
Rheum Dis Clin North Am; 2004 Nov; 30(4):879-98, viii. PubMed ID: 15488699
[TBL] [Abstract][Full Text] [Related]
7. The Swedish ACCES model: predicting the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis.
Haglund U; Svarvar P
Rheumatology (Oxford); 2000 Dec; 39 Suppl 2():51-6. PubMed ID: 11276803
[TBL] [Abstract][Full Text] [Related]
8. Estimating the health-care usage associated with osteoarthritis and rheumatoid arthritis in an older adult population in Ireland.
Doherty E; O'Neill C
J Public Health (Oxf); 2014 Sep; 36(3):504-10. PubMed ID: 24097191
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of an intervention program with the aim to improve at-work productivity for workers with rheumatoid arthritis.
Noben C; Vilsteren MV; Boot C; Steenbeek R; Schaardenburg DV; Anema JR; Evers S; Nijhuis F; Rijk A
J Occup Health; 2017 May; 59(3):267-279. PubMed ID: 28381814
[TBL] [Abstract][Full Text] [Related]
10. The clinical management of rheumatoid arthritis and osteoarthritis: strategies for improving clinical effectiveness.
Scott DL; Shipley M; Dawson A; Edwards S; Symmons DP; Woolf AD
Br J Rheumatol; 1998 May; 37(5):546-54. PubMed ID: 9651084
[No Abstract] [Full Text] [Related]
11. Economic outcomes for celecoxib: a systematic review of pharmacoeconomic studies.
Huelin R; Pokora T; Foster TS; Mould JF
Expert Rev Pharmacoecon Outcomes Res; 2012 Aug; 12(4):505-23. PubMed ID: 22971036
[TBL] [Abstract][Full Text] [Related]
12. An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists.
Bansback NJ; Regier DA; Ara R; Brennan A; Shojania K; Esdaile JM; Anis AH; Marra CA
Drugs; 2005; 65(4):473-96. PubMed ID: 15733011
[TBL] [Abstract][Full Text] [Related]
13. Rheumatology.
Hoare J
Health Serv Manage; 1993; 89(7):24-6. PubMed ID: 10127760
[TBL] [Abstract][Full Text] [Related]
14. Health education for self-management has significant early and sustained benefits in chronic arthritis.
Holman H; Mazonson P; Lorig K
Trans Assoc Am Physicians; 1989; 102():204-8. PubMed ID: 2517854
[No Abstract] [Full Text] [Related]
15. [Are "biologics" in the treatment of rheumatoid arthritis really cost effective?].
Müller-Ladner U
Internist (Berl); 2004 Dec; 45(12):1402-6. PubMed ID: 15517125
[TBL] [Abstract][Full Text] [Related]
16. Use of the ACCES model to predict the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis in Norway.
Svarvar P; Aly A
Rheumatology (Oxford); 2000 Dec; 39 Suppl 2():43-50. PubMed ID: 11276802
[TBL] [Abstract][Full Text] [Related]
17. Evidence suggesting that health education for self-management in patients with chronic arthritis has sustained health benefits while reducing health care costs.
Lorig KR; Mazonson PD; Holman HR
Arthritis Rheum; 1993 Apr; 36(4):439-46. PubMed ID: 8457219
[TBL] [Abstract][Full Text] [Related]
18. Cost-Utility and Cost-Effectiveness Analyses of Face-to-Face Versus Telephone-Based Nonpharmacologic Multidisciplinary Treatments for Patients With Generalized Osteoarthritis.
Cuperus N; van den Hout WB; Hoogeboom TJ; van den Hoogen FH; Vliet Vlieland TP; van den Ende CH
Arthritis Care Res (Hoboken); 2016 Apr; 68(4):502-10. PubMed ID: 26314289
[TBL] [Abstract][Full Text] [Related]
19. [Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany].
Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
Z Rheumatol; 2004 Feb; 63(1):59-75. PubMed ID: 14991279
[TBL] [Abstract][Full Text] [Related]
20. An economic approach to health care.
Homik JE; Suarez-Almazor M
Best Pract Res Clin Rheumatol; 2004 Apr; 18(2):203-18. PubMed ID: 15121040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
